Skip to main content
. 2023 Aug 22;11:1137051. doi: 10.3389/fped.2023.1137051

Table 3.

Outcomes and side effects.

Group A Group B
N. of patients 13 (37.1%) 22 (62.9%)
Outcomes
Need of treatment step-up after anakinra 7.7% 4.5%
Defervescence of fever at 24 h 100% 77.3%
CRP halving at 48 h 76.9% 72.7%
CAA development after anakinra 0% 0%
CRP halving time (days) 2 (1–2) 2 (1–3)
BNP/proBNP halving time (days) 2.5 (2–3) 2 (2–4)
Ejection Fraction normalization time (days) 2 (2–3) 3 (2–9)
Need of ICU admission after anakinra 0%
ICU admission duration after anakinra 5 (4–11)
Time to inotrope support halving (days) 2 (1–3)
MIS-C relapse after anakinra suspension 0% 0%
Side effects
ALT increase during treatment (>2× age range) 30.8% 9.1%
Injection site reaction 4.5%

All the continuous variables are expressed as median and IQR.